Rockwell gains on more Phase III anemia data

Rockwell Medical Technologies Inc. (NASDAQ:RMTI) jumped as much as 14% on Wednesday before closing the day up $0.49 to $6.03 after reporting that Soluble Ferric Pyrophosphate (SFP) met the primary endpoint in a second Phase III trial to treat iron deficiency anemia in chronic kidney disease (CKD) patients requiring hemodialysis. In the CRUISE-2 trial, SFP delivered via hemodialysate concentrate led to a 0.5 g/L reduction in mean hemoglobin from baseline to the end of treatment vs. a 4 g/L reduction for placebo in 286 CKD patients on regular hemodialysis who were receiving stable doses of erythropoietin stimulating agents (ESAs) and who were iron replete (p=0.011). ...